On March 6 and 7, the LRG Research Team met for the second in-person meeting at Brigham & Women’s Hospital in Boston, Mass. The Team had previously met in Portland, Oregon at Oregon Health & [...]
The following article was reprinted from an email alert sent by LegisLink Action Center, a community education service of US Oncology. On September 16, the Centers for Medicare & Medicaid Services (CMS) broadened the scope [...]
Liz Skree at the NIH Pediatric & Wild-type GIST Clinic
Leah Knopp at the NIH Pediatric & Wild-type GIST Clinic
Josalin Dunn at the NIH Pediatric & Wild-type GIST Clinic
Pat George, LRG member and volunteer is well-known in the community. Pat recently took it upon himself to help educate the local students
KIT functions in several distinct cell types. Keep reading to learn about KIT signaling and new approaches for GIST Therapy.
This article explains hereditary GIST. Familial cancer syndrome is a genetic condition that causes an increased risk for specific types of cancers. Familial cancer syndromes account for only five to ten percent of all [...]
Gleevec was approved by the Food and Drug Administration (FDA) to prevent Gastrointestinal Cancer(imatinib mesylate) for a new indication. This will keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor [...]
Gastrointestinal stromal tumors (GISTs) are caused by mutations in the KIT or PDGFRA (platelet-derive growth factor receptor alpha) receptor tyrosine kinase genes and can successfully be treated with imatinib mesylate
